Axsome settles SUNOSI patent litigation, allows generics starting 2040
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/22/2026
- Wall Street indexes dip with technology earnings, rising oil in focus
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- Oil settles up more than 3% to six-week high as Mideast conflict threatens oil transit routes
- Can Alphabet earnings reignite investor enthusiasm for the Magnificent Seven?
- Emirates refusing to take delivery of first 10 Boeing 777X jets
- Intersnack to acquire Utz Brands at $14.25 per share in go-private deal
- Crude Inventory Rose 2 Million Barrels Last Week - EIA
- Wall St ends higher on chip stocks recovery; earnings in focus
- Palo Alto Networks to acquire Embrace to expand observability tools
Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation
June 3, 2026 7:00 AM EDTNEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has resolved all patent litigation related to Axsomes product SUNOSI (solriamfetol). The litigations resulted from submission of Abbreviated New Drug Applications to the U.S. Food and Drug Administration by companies seeking approval to market a generic version of SUNOSI in the United States.
Axsome resolved all outstanding SUNOSI patent litigation upon entering into a settlement... More
